National comparisons of lung cancer survival in England, Norway and Sweden 2001-2004: differences occur early in follow-up

被引:85
作者
Holmberg, Lars [1 ]
Sandin, Fredrik [2 ]
Bray, Freddie [4 ]
Richards, Mike [5 ]
Spicer, James [1 ]
Lambe, Mats [3 ]
Klint, Asa [6 ]
Peake, Mick [7 ]
Strand, Trond-Eirik [4 ]
Linklater, Karen [1 ]
Robinson, David [1 ]
Moller, Henrik [1 ]
机构
[1] Kings Coll London, Sch Med, Div Canc Studies, London SE1 9RT, England
[2] Reg Oncol Ctr, Uppsala, Sweden
[3] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden
[4] Norwegian Canc Registry, Oslo, Norway
[5] St Thomas Hosp, Dept Palliat Med, London, England
[6] Natl Board Hlth & Welf, Swedish Canc Registry, Stockholm, Sweden
[7] Glenfield Gen Hosp, Dept Resp Med, Leicester LE3 9QP, Leics, England
关键词
LONG-TERM SURVIVAL; RELATIVE SURVIVAL; RESECTION; COMPLETENESS; EUROCARE-4; CARCINOMA; EUROPE; WOMEN;
D O I
10.1136/thx.2009.124222
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background Countries with a similar expenditure on healthcare within Europe exhibit differences in lung cancer survival. Survival in lung cancer was studied in 2001-2004 in England, Norway and Sweden. Methods Nationwide cancer registries in England, Norway and Sweden were used to identify 250 828 patients with lung cancer from England, 18 386 from Norway and 24 886 from Sweden diagnosed between 1996 and 2004, after exclusion of patients registered through death certificate only or with missing, zero or negative survival times. 5-Year relative survival was calculated by application of the period approach. The excess mortality between the countries was compared using a Poisson regression model. Results In all subcategories of age, sex and follow-up period, the 5-year survival was lower in England than in Norway and Sweden. The age-standardised survival estimates were 6.5%, 9.3% and 11.3% for men and 8.4%, 13.5% and 15.9% for women in the respective countries in 2001-2004. The difference in excess risk of dying between the countries was predominantly confined to the first year of follow-up. The relative excess risk ratio during the first 3 months of follow-up comparing England with Norway 2001-2004 varied between 1.23 and 1.46, depending on sex and age, and between 1.56 and 1.91 comparing England with Sweden. Conclusion Access to healthcare and population awareness are likely to be major reasons for the differences, but it cannot be excluded that diagnostic and therapeutic activity play a role. Future improvements in lung cancer management may be seen early in follow-up.
引用
收藏
页码:436 / 441
页数:6
相关论文
共 33 条
[1]   Do women live longer following lung resection for carcinoma? [J].
Alexiou, C ;
Onyeaka, CVP ;
Beggs, D ;
Akar, R ;
Beggs, L ;
Salama, FD ;
Duffy, JP ;
Morgan, WE .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2002, 21 (02) :319-325
[2]  
[Anonymous], 2005, STAT STAT SOFTW REL
[3]  
[Anonymous], 2008, WHO report on the global tobacco epidemic, 2008: The MPOWER package
[4]  
[Anonymous], 2007, R LANG ENV STAT COMP
[5]   The completeness of the Swedish Cancer Register - a sample survey for year 1998 [J].
Barlow, Lotti ;
Westergren, Kerstin ;
Holmberg, Lars ;
Talback, Mats .
ACTA ONCOLOGICA, 2009, 48 (01) :27-33
[6]   The female gender has a positive effect on survival independent of background life expectancy following surgical resection of primary non-small cell lung cancer:: a study of absolute and relative survival over 15 years [J].
Båtevik, R ;
Grong, K ;
Segadal, L ;
Stangeland, L .
LUNG CANCER, 2005, 47 (02) :173-181
[7]   Histological subtype of lung cancer in relation to socio-economic deprivation in South East England [J].
Bennett, Victoria A. ;
Davies, Elizabeth A. ;
Jack, Ruth H. ;
Mak, Vivian ;
Moller, Henrik .
BMC CANCER, 2008, 8 (1)
[8]   Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study [J].
Berrino, Franco ;
De Angelis, Roberta ;
Sant, Milena ;
Rosso, Stefano ;
Lasota, Magdalena B. ;
Coebergh, Jan W. ;
Santaquilani, Mariano .
LANCET ONCOLOGY, 2007, 8 (09) :773-783
[9]  
Bouchardy C, 1999, CANCER, V86, P2229, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2229::AID-CNCR9>3.0.CO
[10]  
2-K